SMT’s Supraflex stent clinically at par with Abbott’s Xience , with numerically better outcome:… Patients who got Supraflex stent had target lesion failure occur among 6.9 per cent at 720 days vs 7.9 per cent of Xience…
Indian stent makers: No more on the fringes of business In India's price sensitive market, domestic stent manufacturers have fared well and are now capturing global markets By Raelene…
